Skip to main content

Research News

 

Clinical courses

 

Clinical courses

  • CAMH develops potential new drug treatment for multiple sclerosis

    CAMH-led pre-clinical studies using a small molecule drug have shown promise as a potential new treatment for multiple sclerosis (MS). The results have been published today in the journal Science Advances

  • Sarclisa (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant

    The Phase 3 IMROZ trial evaluating the investigational use of Sarclisa (isatuximab) in combination with standard-of-care bortezomib, lenalidomide and dexamethasone (VRd) met its primary endpoint at a planned interim analysis for efficacy, demonstrating statistically significant improvement in progression-free survival (PFS) compared with VRd alone in transplant-ineligible patients with newly diagnosed multiple myeloma (MM). This is also the second Phase 3 trial investigating Sarclisa in newly diagnosed patients to show superiority versus standard of care.

  • Protein found in brain linked to frontotemporal dementia

    An international team of researchers including experts at the Indiana University School of Medicine has identified a protein found in the brains of people with frontotemporal dementia (FTD), discovering a new target for potential treatments for the disease.

  • Use of anticoagulant drug after aortic valve replacement lowers mortality risk, study

    Patients who received the anticoagulant drug warfarin after bioprosthetic aortic valve replacement had lower incidence of mortality and a decreased risk of blood clots, according to a retrospective study published in Mayo Clinic Proceedings.

  • Surgery beneficial for some children with mild sleep-disordered breathing

    Surgical removal of the tonsils and adenoids in children with snoring and mild breathing problems during sleep appears to improve their sleep, quality of life, and blood pressure a year after surgery, a clinical trial supported by the National Institutes of Health has found. The study, funded by the National Heart, Lung, and Blood Institute (NHLBI), part of NIH, is believed to be the first large, randomized trial to address the effects of adenotonsillectomy on children with mild sleep-disordered breathing (SDB).

  • Leukemia cells activate cellular recycling program

    To speed up their growth, leukemia cells typically activate the recycling of cellular structures – enabling them to dispose of defective components and better supply themselves with building materials. Researchers at Goethe University Frankfurt have now shown that leukemia cells with a very common mutation activate specific genes that are important for this recycling process. Their findings, published in the journal Cell Reports, open up new therapeutic options for the future.

  • Breakthroughs in Nanosized Contrast Agents and Drug Carriers Through Self-Folding Molecules

    Self-folding polymers containing gadolinium forming nanosized complexes could be the key to enhanced magnetic resonance imaging and next-generation drug delivery, as demonstrated by scientists at Tokyo Tech. Thanks to their small size, low toxicity, and good tumor accumulation and penetration, these complexes represent a leap forward in contrast agents for cancer diagnosis, as well as neutron capture radiotherapy.

  • Loss of Auditory Nerve Fibers Uncovered in Individuals with Tinnitus

    A new study from Mass Eye and Ear investigators shows that individuals who report tinnitus, which present as a ringing in the ears in more than one out of ten adults worldwide, are experiencing auditory nerve loss that is not picked up by conventional hearing tests.

  • A patch of protection against Zika virus

    A simple-to-apply, needle-free vaccine patch is being developed to protect people from the potentially deadly mosquito-borne Zika virus.

    A prototype using The University of Queensland-developed and Vaxxas-commercialised high-density microarray patch (HD-MAP) has delivered a University of Adelaide-developed vaccine and elicited an effective immune response to Zika virus in mice.

  • Nano-sized cell particles are promising intervention tool in treating infectious diseases

    The COVID-19 pandemic demonstrated the importance of being prepared with drug interventions to contain viral outbreaks that can otherwise have devastating consequences. In preparing for the next pandemic—or Disease X, there is an urgent need for versatile platform technologies that could be repurposed upon short notice, to combat infectious outbreaks.

Subscribe to Research News